Lilly Financial Results: Q3 2019
On October 23, Lilly announced its financial results, including earnings, for the third quarter of 2019.
"Lilly continued to deliver strong results in the third quarter, due in large part to the growth of our newer medicines and our ability to effectively manage costs while supporting global launches in highly competitive classes and funding our next generation of new therapies," said Dave Ricks, Lilly's chairman and CEO. "Lilly's revenue growth is being driven by volume, not price, as more and more patients are benefiting from our recently launched medicines. Our sustained investments in oncology, diabetes, immunology, and neuroscience research continue to be productive, with several new medicines expected to be submitted, launch and then reach patients over the next few years
Read the press release
Listen to the investor webcast
Download the investor presentation
View Lilly's clinical development pipeline
Read Lilly executive committee biographies
- View Lilly's key facts
For more information, visit Lilly's Investor Relations website.